← Back
$GENB All transactions

Generate Biomedicines, Inc.

C

$ Value

$0

Shares

17,016,215

Price

$0

Filed

Mar 2

Insider

Name

AFEYAN NOUBAR

Title

CIK

0001222012

Roles

Director 10% Owner

Transaction Details

Transaction Date

2026-03-02

Code

C

Table

Derivative

Ownership

Indirect

Equity Swap

No

Shares After

Footnotes

Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. | Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. | The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Filing Info

Accession No.

0001193125-26-085888

Form Type

4

Issuer CIK

0002100782

AFEYAN NOUBAR's History

Date Ticker Type Value
2026-03-02 GENB C
2026-03-02 GENB C
2026-03-02 GENB C
2026-03-02 GENB C
2026-03-02 GENB C
2026-03-02 GENB $25.0M
2026-03-02 GENB $25.0M
2026-03-02 GENB $25.0M
2026-03-02 GENB C $0
2026-03-02 GENB C $0

Other Insiders at GENB (90d)

Insider Bought Sold Last
AFEYAN NOUBAR $150.0M 2026-03-02
Nally Michael
Chief Executive Officer
$240K 2026-03-04
Silvers Jason
President & CFO
$32K 2026-03-02
Mendillo Jane L $24K 2026-03-02
Grous Beth
Chief People Officer
$5K 2026-03-02
Fanucci Marsha 2026-02-26
Simonian Nancy A 2026-02-26
Bancel Stephane 2026-03-02
Martin Sean
Chief Legal Officer & GC
2026-02-26
ARNOLD FRANCES 2026-02-26
Vessey Rupert 2026-02-26
Parker Paul Gray 2026-02-26
Grigoryan Gevorg
Chief Technology Officer
2026-02-26
Lee Laurie Anne
Chief Medical Officer
2026-02-26